Perspective Therapeutics reports 50% response rate in highest-dose cohort of VMT-α-NET trial

Bitget2026/10/23 14:50

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Perspective Therapeutics announced interim Phase 1/2a results showing tumor responses and sustained disease control with VMT-α-NET in advanced SSTR2-positive neuroendocrine tumors.
Results are being presented at the ESMO Congress 2026 in Madrid, running October 23-27.
No dose-limiting toxicities or adverse event-related treatment discontinuations were reported; some patients experienced severe side effects, including kidney events.
Phase 3 site preparations are targeted for completion around year-end 2026, with trial initiation expected in 2027 following FDA alignment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231049PRIMZONEFULLFEED9852132) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Perspective Therapeutics reports 50% response rate in highest-dose cohort of VMT-α-NET trial

You may also like

Crypto prices